9,975 Shares in Celgene Corporation (CELG) Purchased by Scholtz & Company LLC

Scholtz & Company LLC bought a new stake in Celgene Corporation (NASDAQ:CELG) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,975 shares of the biopharmaceutical company’s stock, valued at approximately $1,295,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Capital Counsel LLC NY lifted its holdings in Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares during the last quarter. Sowell Financial Services LLC lifted its holdings in Celgene by 0.5% in the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 13 shares during the last quarter. South Texas Money Management Ltd. lifted its holdings in Celgene by 0.6% in the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC lifted its holdings in Celgene by 0.9% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 18 shares during the last quarter. Finally, Savant Capital LLC lifted its holdings in Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 20 shares during the last quarter. 80.17% of the stock is owned by institutional investors.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.

Celgene Corporation (CELG) opened at $106.09 on Friday. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a market capitalization of $80,881.07, a P/E ratio of 16.05, a P/E/G ratio of 0.79 and a beta of 1.78. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

A number of brokerages have weighed in on CELG. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Thursday, October 5th. Royal Bank Of Canada reissued a “buy” rating and issued a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene in a research note on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene in a research note on Tuesday, September 26th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $139.57.

TRADEMARK VIOLATION WARNING: “9,975 Shares in Celgene Corporation (CELG) Purchased by Scholtz & Company LLC” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/09/9975-shares-in-celgene-corporation-celg-purchased-by-scholtz-company-llc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply